Literature DB >> 2188586

Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase.

B Fantin1, B Pangon, G Potel, F Caron, E Vallée, J M Vallois, J Mohler, A Buré, A Philippon, C Carbon.   

Abstract

We studied the efficacy of sulbactam, a beta-lactamase inhibitor, in combination with ceftriaxone in vitro and in experimental endocarditis due to an Escherichia coli strain producing an extended-spectrum beta-lactamase most similar to SHV-2, a new mechanism of resistance to broad-spectrum cephalosporins among members of the family Enterobacteriaceae. In vitro, ceftriaxone demonstrated an important inoculum effect (MICs were 2 and 256 micrograms/ml with 5 X 10(5) and 5 X 10(7) CFU of inoculum per ml, respectively). Sulbactam inhibited the beta-lactamase degradation of ceftriaxone and enhanced the killing by ceftriaxone with both inocula tested. In vivo, sulbactam (100 mg/kg every 8 h) or ceftriaxone (15 or 30 mg/kg every 24 h) alone were ineffective after a 4-day therapy. The addition of sulbactam to ceftriaxone (15 mg/kg) or to the ceftriaxone (15 mg/kg)-netilmicin (6 mg/kg every 24 h) combination produced a reduction of 2 log10 CFU/g of vegetation greater than that produced by therapy without sulbactam. The sulbactam-ceftriaxone (30 mg/kg) combination produced a reduction of almost 5 log10 CFU/g of vegetation greater than that produced by single-drug therapy (P less than 0.01), sterilized five of eight vegetations (versus none of seven for ceftriaxone [30 mg/kg] alone; P less than 0.05), and was as effective as the ceftriaxone (15 mg/kg)-sulbactam-netilmicin combination. We concluded that (i) SHV-2 production was responsible for ceftriaxone failure in vivo, probably because of the high inoculum present in vegetations; (ii) sulbactam used in a regimen which provided levels in serum constantly above 4 micrograms/ml and a vegetation/serum peak ratio of approximately 1:3 enhanced the activity of a broad-spectrum cephalosporin in a severe experimental infection; and (iii) the highest dose of ceftriaxone in combination with sulbactam was as effective as the lowest dose of ceftriaxone plus sulbactam plus an aminoglycoside.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188586      PMCID: PMC171647          DOI: 10.1128/AAC.34.4.581

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.

Authors:  C Kliebe; B A Nies; J F Meyer; R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

2.  Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use.

Authors:  L Lees; J A Milson; A K Knirsch; K Greenhalgh
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

3.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

4.  Properties of PSE-2 beta-lactamase and genetic basis for its production in Pseudomonas aeruginosa.

Authors:  A M Philippon; G C Paul; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

5.  Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.

Authors:  B Pangon; V Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

6.  Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae.

Authors:  C Brun-Buisson; P Legrand; A Philippon; F Montravers; M Ansquer; J Duval
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

7.  Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents.

Authors:  P F Dougherty; D W Yotter; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

8.  Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography.

Authors:  H J ROgers; I D Bradbrook; P J Morrison; R G Spector; D A Cox; L J Lees
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

9.  Ion pair high-performance liquid chromatographic assay for ceftriaxone.

Authors:  G G Granich; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

10.  Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.

Authors:  R G Washburn; D T Durack
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

View more
  20 in total

Review 1.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 3.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

Authors:  F Caron; L Gutmann; A Bure; B Pangon; J M Vallois; A Pechinot; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.

Authors:  L B Rice; J D Yao; K Klimm; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 6.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

7.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

8.  Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.

Authors:  C Thauvin-Eliopoulos; M F Tripodi; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

9.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

Review 10.  Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Authors:  D L Paterson; W C Ko; A Von Gottberg; J M Casellas; L Mulazimoglu; K P Klugman; R A Bonomo; L B Rice; J G McCormack; V L Yu
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.